Guillermo Garcia-Manero, MD, discusses the developmental progress of emavusertib for the treatment of acute myeloid leukemia and myelodysplastic syndromes.

Curis, Inc. shares promising results from the TakeAim Leukemia study on emavusertib, showing substantial effectiveness in R/R AML patients.

LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and...

Curis, Inc. has announced a public offering valued at $5.6 million to advance its pioneering research. This investment will aid in developing its promising treatments.

Curis, Inc. has successfully dosed the first five patients in its groundbreaking TakeAim CLL study with emavusertib, aimed at enhancing Chronic Lymphocytic Leukemia treatment.

Curis (NASDAQ: CRIS) reported an enrollment milestone in its TakeAim CLL study evaluating emavusertib, an oral IRAK4/FLT3 inhibitor, in Chronic Lymphocytic Leukemia. The company has now dosed the first five patients, after previously opening 11 sites and consenting 10 patients.Curis reaffirmed its expectation to present initial data from 5–10 CLL patients in December 2026. The study combines emavusertib with the BTK inhibitor zanubrutinib to achieve dual NF-kB pathway blockade (BCR and TLR), aiming for deeper responses, complete remissions and undetectable minimal residual disease. According to Curis, the regimen appears well tolerated so far, with possible early signs of deepening responses, although patient numbers remain small.

LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study...

Curis, Inc. has reported encouraging new clinical data for their drug emavusertib, aimed at treating lymphoma. Learn more about recent trial developments.

Updated Clinical Data in PCNSL Increased Guidance on Year-End Data in CLL Company to Host Webcast at 8:30 a.m. ET LEXINGTON, Mass., July 22, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available,...

Curis (NASDAQ: CRIS) reported updated clinical data for emavusertib (CA-4948) in Primary CNS Lymphoma (PCNSL) from the TakeAim Lymphoma study and updated enrollment guidance for the TakeAim CLL Phase 2 study, and will host a webcast on July 22, 2026 at 8:30 a.m. ET.In PCNSL as of July 1, 2026, BTK inhibitor (BTKi)-naïve patients showed a 100% objective response rate (ORR) in 5 of 5 evaluable patients and 86% ORR in all 7 patients, compared with 71% (5 of 7) in prior data as of May 1, 2025. BTKi-experienced patients demonstrated a 33% ORR in 10 of 30 evaluable patients and 26% ORR in all 39 patients, versus 27% (7 of 26) previously.For TakeAim CLL, Curis disclosed that 10 patients have now been consented, with the first five expected to be dosed by the end of July 2026. The company increased its year-end 2026 data guidance from 5 patients to 5–10 patients.

Emavusertib yields remissions in high-risk MDS with spliceosome mutations, per ASH 2023 TakeAim trial data."

Curis has opened enrolment at 11 clinical sites for its Phase II TakeAim CLL trial, assessing the oral small molecule inhibitor emavusertib along with zanubrutinib for patients with CLL.

Curis, Inc. announces milestone with the first six patient consents in its TakeAim CLL study, testing innovative treatment for chronic lymphocytic leukemia.

Curis, Inc. has released its business and financial updates for Q1 2026, highlighting advancements in clinical trials and financial challenges.

Curis, Inc. shares its Q4 2025 financial results and updates on emavusertib trials, showcasing significant advancements in lymphoma treatment strategies and financial recovery.

Curis, Inc., a biotechnology firm, has successfully closed a private placement financing, raising up to $80.8 million to advance drug development.

Curis, Inc. has announced a private placement expected to deliver up to $80.8 million. The financing aims to support research and development initiatives for its oncology drug, emavusertib.

Curis, Inc. reports updated, encouraging data from its ongoing frontline AML triplet study, showcasing potential breakthroughs in treatment options for patients.

Curis, Inc. will present groundbreaking clinical and preclinical data on emavusertib at the upcoming 30th SNO Meeting in November 2025.

Curis, Inc. announces its third-quarter financial results, showcasing progress in clinical studies and ongoing developments for emavusertib in treating multiple cancers.

Curis, Inc. has reported the grant of stock options to new employees in compliance with NASDAQ regulations, enhancing its workforce for future growth.

Curis, Inc. is gearing up for major healthcare conferences this September to discuss its oral small molecule IRAK4 inhibitor, emavusertib. CEO James Dentzer will present insights on advancements.

Curis, Inc. highlights positive developments in its ongoing clinical studies in its latest business update, paving the way for future treatments.